NCT02198352已完成1 期
A Double-blind, Placebo-controlled Single Rising Dose Tolerability Study (Parallel Groups) in Healthy Male and Female Volunteers After Intravenous Administration of BIBN 4096 BS (Dosage: 0.1 - 10 mg)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 55
- 主要终点
- Number of subjects with adverse events
研究概览
简要总结
The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single intravenous administration of increasing doses in healthy male and female volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants should be healthy males and females
- •Age range from 21 to 50 years
- •Within +- 20% of their normal weight (Broca-Index)
- •All female volunteers must use a safe contraception (i.e. oral contraceptive, spiral; sterilized) and must have a negative pregnancy test
- •In accordance with Good Clinical Practice (GCP) and local legislation each volunteers are supposed to give their written informed consent prior to admission to the study
- •Each subject will have his medical history taken and will receive a complete medical examination (incl. blood pressure and pulse rate measurements) as well as a 12-lead Electrocardiogram (ECG) within 14 days before the first administration of the test substance.
- •Haematopoietic, hepatic and renal function test will be carried out in the laboratory
- •The subjects will fast for 12 hours before collection of specimens for all laboratory evaluations
排除标准
- •Volunteers will be excluded from the study if the results of the medical examination or laboratory tests (especially those which indicate liver malfunction) are judged by the clinical investigator to differ significantly from normal clinical values
- •Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Volunteers with diseases of the central nervous system (such as epilepsy) or with psychiatric disorders
- •History of orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of a drug with a long half-life (>= 24 hours) within ten half-lives of the respective drug before enrolment in the study
- •Use of any other drugs which might influence the results of the trial during the week previous to the start of the study
- •Participation in another study with an investigational drug within the last two months preceding this study
- •Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
- •Inability to refrain from smoking on study days
- •Alcohol abuse (> 40g/day)
- •Drug abuse
- •Blood donation ( >= 100 ml) within the last 4 weeks
- •Excessive physical activities (e.g. competitive sports) within the last week before the study
- •Pregnant and/or lactating volunteers
研究组 & 干预措施
BIBN 4096 BS - in single rising doses
Experimental
干预措施: BIBN 4096 BS - in single rising doses (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of subjects with adverse events
时间窗: up to 2 months
Number of subjects with abnormal changes in laboratory parameters
时间窗: up to 8 days after last study day
Number of subjects with clinically significant changes in vital signs (blood pressure, pulse rate, respiratory rate)
时间窗: up to 8 days after last study day
Number of subjects with clinically significant changes in ECG (Electrocardiogram)
时间窗: up to 8 days after last study day
Number of subjects with clinically relevant changes in venous-occlusion plethysmography
时间窗: up to 8 hours after drug administration
次要结局
- MRT (Mean residence time of the analyte in the body)(up to 24 hours after drug administration)
- Cmax (Maximum measured concentration of the analyte in plasma)(up to 24 hours after drug administration)
- CL (Total clearance of the analyte in plasma following extravascular administration)(up to 24 hours after drug administration)
- Vss (Volume of distribution at steady state)(up to 24 hours after drug administration)
- Percentage of urinary excretion of BIBN 4096 BS(up to 24 hours after drug administration)
- Vz (Apparent volume of distribution during the terminal elimination phase)(up to 24 hours after drug administration)
- AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 24 hours after drug administration)
- t½ (Terminal half-life of the analyte in plasma)(up to 24 hours after drug administration)
研究者
相似试验
已完成
1 期
Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male VolunteersHealthyNCT02222961Boehringer Ingelheim60
已完成
1 期
Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CLHealthyNCT02222974Boehringer Ingelheim84
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy SubjectsDepressionNCT00949767Bristol-Myers Squibb64
已完成
1 期
A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477Healthy VolunteersNCT02870400Regeneron Pharmaceuticals41
已完成
1 期
Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese DescentHealthyNCT01081821Johnson & Johnson Pharmaceutical Research & Development, L.L.C.61